Physician profile
Rebecca Rich
NPI 1740809458
$5,235.26
in general payments reported to CMS, 2019-2025
38 companies · $540 in 2025
The $540 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,481 · 2022: $813 · 2023: $1,429 · 2024: $972 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,785 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,784.81 |
| Education | $156.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $447.59 | 2021-2024 | Calquence |
| Incyte Corporation | $427.32 | 2021-2024 | Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $332.16 | 2021-2025 | Enhertu |
| Pharmacosmos Therapeutics INC. | $305.70 | 2021-2025 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $293.29 | 2022-2024 | |
| Agios Pharmaceuticals, INC. | $273.90 | 2021-2023 | Pyrukynd |
| Seagen INC. | $255.83 | 2021-2023 | Padcev, Adcetris |
| Eisai INC. | $202.73 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $199.07 | 2023-2024 | |
| Gilead Sciences, INC. | $191.05 | 2021-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $156.54 | 2023-2025 | Jemperli, Ojjaara, Blenrep |
| E.R. Squibb & Sons, L.L.C. | $134.39 | 2022-2025 | Opdivo |
| Foundation Medicine, INC. | $129.65 | 2023 | |
| Novocure INC. | $129.35 | 2023 | Optune |
| Emd Serono, INC. | $122.49 | 2023 | Bavencio |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $120.12 | 2021 | |
| Stemline Therapeutics INC. | $120.00 | 2023 | Orserdu |
| Merck Sharp & Dohme LLC | $117.98 | 2024-2025 | Keytruda |
| Dova Pharmaceuticals | $117.00 | 2021 | |
| Pharmaessentia USA Corporation | $115.79 | 2025 | Besremi |
| Sobi, INC | $111.52 | 2022 | |
| Mirati Therapeutics, INC. | $104.00 | 2023-2024 | Krazati |
| Pharmacyclics LLC, An Abbvie Company | $102.13 | 2021 | |
| Amgen INC. | $96.27 | 2021 | |
| Kite Pharma, INC. | $92.08 | 2021 | |
| Abbvie INC. | $82.12 | 2023-2025 | |
| Genentech USA, INC. | $81.11 | 2021 | |
| Lilly USA, LLC | $71.46 | 2023-2024 | Jaypirca, Retevmo, Verzenio |
| Pfizer INC. | $63.90 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $42.32 | 2023-2024 | Givlaari |
| Celgene Corporation | $37.23 | 2023 | Opdualag, Pomalyst |
| Beigene USA, INC. | $32.12 | 2023-2024 | Brukinsa |
| Astellas Pharma US INC | $30.37 | 2025 | Padcev, Xtandi |
| Ipsen Biopharmaceuticals, INC | $22.23 | 2024 | Onivyde, Somatuline Depot |
| Regeneron Healthcare Solutions, INC. | $22.14 | 2023 | Libtayo |
| Taiho Oncology, INC. | $21.68 | 2024 | |
| Springworks Therapeutics, INC. | $18.61 | 2024 | Ogsiveo |
| Coherus Oncology, INC. | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Rich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.